2025-09-23 - Analysis Report
Okay, let's analyze the provided data for Merck & Co Inc (MRK).  Here's a report summarizing the information:

## Merck & Co Inc (MRK) Stock Analysis

**Company Overview:** Merck & Co Inc is a global pharmaceutical company focused on developing and marketing medicines and vaccines.

**1. Performance vs. S&P 500 (VOO)**

*   **MRK Cumulative Return:** -10.79%
*   **VOO Cumulative Return:** 106.97%
*   **Absolute Divergence (Current):** -116.8%

**Analysis:**  MRK has significantly underperformed the S&P 500. The current divergence is at the lowest point in the observed range.

**Alpha, Beta Analysis Table:**

| Year       | CAGR    | MDD      | Alpha   | Beta   | Cap(B) |
|------------|---------|----------|---------|--------|--------|
| 2015-2017  | 5.0%    | 58.2%    | -24.0%  | -0.0   | 134.1  |
| 2016-2018  | 43.0%   | 66.4%    | 25.0%   | -0.1   | 182.1  |
| 2017-2019  | 40.0%   | 66.4%    | 11.0%   | 0.3    | 216.8  |
| 2018-2020  | 20.0%   | 66.4%    | 0.0%    | 0.3    | 195.0  |
| 2019-2021  | -1.0%   | 65.6%    | -50.0%  | 0.3    | 191.4  |
| 2020-2022  | 13.0%   | 69.5%    | 11.0%   | 0.3    | 277.1  |
| 2021-2023  | 31.0%   | 69.5%    | 13.0%   | 0.3    | 272.3  |
| 2022-2024  | -7.0%   | 69.5%    | -33.0%  | 0.2    | 248.5  |
| 2023-2025  | -63.0%  | 71.5%    | -122.0% | 0.5    | 203.6  |

**Analysis:**

*   **CAGR:**  Fluctuates significantly, with recent periods showing negative returns.
*   **MDD:** High Maximum Drawdown values indicate significant price volatility and risk.
*   **Alpha:**  Generally negative, especially in recent years, indicating underperformance relative to the market.
*   **Beta:**  Low Beta values suggest that the stock is generally less sensitive to market movements. Beta has been increasing recently, showing higher correlation to market.
*   **Cap(B):** Market capitalization shows change of company size(B = Billions of USD)

**2. Recent Stock Price Action**

*   **Current Price:** 81.51
*   **Last Market Price:** 80.4
*   **Previous Close:** 81.51
*   **Change:** -1.36
*   **5-Day Moving Average:** 81.258
*   **20-Day Moving Average:** 83.6817
*   **60-Day Moving Average:** 82.4823

**Analysis:** The stock is trading below its 20-day and 60-day moving averages, indicating a short-term downtrend. The price drop from the previous close and the negative change in the last market suggest recent selling pressure.

**3. Technical Indicators & Hybrid Signal**

*   **Market Risk Indicator (MRI):** 0.3367 (Low Risk)
*   **RSI:** 35.94 (Approaching Oversold)
*   **PPO:** -0.5428 (Negative, Suggesting Downtrend)
*   **Hybrid Signal:** Cash_69%_Sell 0.9% of holdings (4 shares - Caution - MRI:0.34)
*   **20-Day Relative Divergence Change:** -0.1 (Short-term Decrease)
*   **Expected Return (%):** -1427.1%

**Analysis:**

*   The RSI is nearing oversold territory, which *could* signal a potential bounce.
*   The negative PPO confirms the downtrend.
*   The Hybrid Signal suggests a cautious approach, recommending a slight sell-off and holding a significant cash position.
*   The large negative expected return is a serious concern.
*   The negative price change in the last market indicates ongoing downward pressure.

**4. Recent News & Significant Events**

*   **FDA Grants Breakthrough Therapy Designation:** Positive news regarding Raludotatug Deruxtecan for ovarian cancer.
*   **Merck Snags A Key Approval:**  Positive, potentially mitigating concerns about patent expiration.
*   **FDA Clears Merck's One-Minute Cancer Shot:** Positive news, potentially improving treatment efficiency.
*   **MSD wins SC Keytruda approval:** Positive news for Keytruda's future.
*   **Merck (MRK) Stock Sinks As Market Gains:** Negative price action despite market gains.

**Analysis:**  Mixed news. While there are positive developments regarding FDA approvals and therapies, the stock is underperforming, suggesting market concerns outweigh these positive catalysts. The Keytruda approval is significant, but analysts are skeptical of its immediate impact.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 2.00 (Buy)
*   **Number of Opinions:** 25
*   **Target Price (Avg/High/Low):** 101.60 / 141.00 / 82.00

**Analysis:**  Despite the recent underperformance, analysts generally have a positive outlook on MRK. The average target price suggests significant upside potential.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-08-05 | 1.76 | 15.81 B$   |
| 2025-05-02 | 2.01 | 15.53 B$   |
| 2024-11-06 | 1.25 | 16.66 B$   |
| 2024-08-05 | 2.15 | 16.11 B$   |
| 2025-08-05 | 2.15 | 16.11 B$   |

**Analysis:** Recent EPS has fluctuated. Revenue figures are relatively stable, but EPS volatility might be a concern for investors.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $15.81B   | 77.50%        |
| 2025-03-31 | $15.53B   | 77.98%        |
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-06-30 | $48.99B   | 9.04%     |
| 2025-03-31 | $48.34B   | 10.51%    |
| 2024-12-31 | $46.31B   | 8.08%     |
| 2024-09-30 | $44.50B   | 7.09%     |
| 2024-06-30 | $43.58B   | 12.52%    |

**Analysis:** Revenue is relatively stable.  Profit margins are strong. Equity is growing, but ROE has fluctuated.  The recent ROE of 9.04% is reasonable but lower than some previous quarters.

**7. 종합 Conclusion:**

Merck (MRK) is facing headwinds. While the company has secured important FDA approvals and maintains strong profit margins, the stock is significantly underperforming the S&P 500. Technical indicators suggest a downtrend, and the hybrid signal recommends a cautious approach. The substantial negative expected return is a major concern.

While analyst consensus remains positive, investors should carefully consider the risks, including the negative price action, competitive pressures (patent cliff), and uncertain market sentiment. The analyst target prices suggest a potential upside, but the stock's recent performance warrants caution. Further research into the specific factors driving the underperformance is recommended before making any investment decisions.
